A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BLU-782 When Administered Orally to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs BLU-782 (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Blueprint Medicines
- 06 Nov 2019 Status changed from recruiting to completed.
- 16 Oct 2019 According to a Blueprint Medicines media release, preliminary data were presented at the American Society of Bone and Mineral Research Annual Meeting in September 2019.
- 16 Oct 2019 Results presented in a Blueprint Medicines Media Release.